BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND PR, PGR, progesterone receptor AND Treatment
543 results:

  • 1. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
    Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients.
    Derbes R; Hakun J; Elbich D; Master L; Berenbaum S; Huang X; Buxton OM; Chang AM; Truica CI; Sturgeon KM
    Sci Rep; 2024 Apr; 14(1):8338. PubMed ID: 38594369
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Human Epidermal Growth Factor receptor 2-Low Breast cancer brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
    Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
    JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
    Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
    BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.
    Zhang Q; Li Y; Zhang Y; Deng Z; Ding Y
    World J Surg Oncol; 2024 Feb; 22(1):50. PubMed ID: 38336701
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
    Lu Y; Liao L; Du K; Mo J; Zou X; Liang J; Chen J; Tang W; Su L; Wu J; Zhang J; Tan Y
    BMC Cancer; 2024 Jan; 24(1):133. PubMed ID: 38273249
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules.
    Iragavarapu-Charyulu V; Shakya R; Robinson P; Guzmán E; Tyulmenkova A; Pino JL; Isgor C
    Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38131223
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Radiogenomic landscape: Assessment of specific phagocytosis regulators in lower-grade gliomas.
    Maimaiti A; Abulaiti A; Tang B; Dilixiati Y; Li X; Yakufu S; Wang Y; Jiang L; Shao H
    Exp Biol Med (Maywood); 2023 Dec; 248(23):2289-2303. PubMed ID: 38062999
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
    Hepner A; Versluis JM; Wallace R; Allayous C; Brown LJ; Trojaniello C; Gerard CL; Jansen YJ; Bhave P; Neyns B; Haydon A; Michielin O; Mangana J; Klein O; Shoushtari AN; Warner AB; Ascierto PA; McQuade JL; Carlino MS; Zimmer L; Lebbe C; Johnson DB; Sandhu S; Atkinson V; Blank CU; Lo SN; Long GV; Menzies AM
    Eur J Cancer; 2024 Jan; 196():113441. PubMed ID: 37988842
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.
    Zhong X; Lin Y; Zhang W; Bi Q
    Sci Rep; 2023 Oct; 13(1):18301. PubMed ID: 37880320
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A Web-based Prediction Model for Early Death in Patients With Metastatic Triple-negative Breast cancer.
    Pan WK; Ren SY; Zhu LX; Lin BC
    Am J Clin Oncol; 2024 Feb; 47(2):71-80. PubMed ID: 37871164
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
    Strowd R; Ellingson B; Raymond C; Yao J; Wen PY; Ahluwalia M; Piotrowski A; Desai A; Clarke JL; Lieberman FS; Desideri S; Nabors LB; Ye X; Grossman S
    J Neurooncol; 2023 Oct; 165(1):101-112. PubMed ID: 37864646
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.
    Pu X; Zhou Y; Kong Y; Chen B; Yang A; Li J; Li K; Xu Y; Wu L
    BMC Cancer; 2023 Oct; 23(1):982. PubMed ID: 37840124
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
    Mantica M; Drappatz J; Lieberman F; Hadjipanayis CG; Lunsford LD; Niranjan A
    J Neurooncol; 2023 Aug; 164(1):179-190. PubMed ID: 37515669
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
    Lopez J; Lai-Kwon J; Molife R; Welsh L; Tunariu N; Roda D; Fernández-García P; Lladó V; McNicholl AG; Rosselló CA; Taylor RJ; Azaro A; Rodón J; Sludden J; Veal GJ; Plummer R; Urruticoechea A; Lahuerta A; Mujika K; Escribá PV
    Br J Cancer; 2023 Sep; 129(5):811-818. PubMed ID: 37488446
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. HR+/HER2- Advanced Breast cancer treatment in the First-Line Setting: Expert Review.
    Jerzak KJ; Bouganim N; Brezden-Masley C; Edwards S; Gelmon K; Henning JW; Hilton JF; Sehdev S
    Curr Oncol; 2023 Jun; 30(6):5425-5447. PubMed ID: 37366894
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
    Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
    JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Combining Pr
    Mandl GA; Vettier F; Tessitore G; Maurizio SL; Bietar K; Stochaj U; Capobianco JA
    ACS Appl Bio Mater; 2023 Jun; 6(6):2370-2383. PubMed ID: 37267436
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients.
    Griguolo G; Aldegheri V; Bottosso M; Pittaro A; Caumo F; Guarascio MC; Pouderoux S; Busato F; Miglietta F; Jacot W; Dieci MV; Darlix A; Guarneri V
    Int J Cancer; 2023 Sep; 153(6):1217-1226. PubMed ID: 37243480
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.
    Marinoff AE; Aaronson K; Agrawal AK; Braun BS; Golden C; Huang BJ; Michlitsch J; Southworth E; Thrall A; Vo KT; Stieglitz E
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30335. PubMed ID: 37036306
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 28.